Trial
NCT04606563
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
University of British Columbia
Collaborators
Canadian Institutes of Health Research (CIHR)
Condition
Covid19
Intervention
Losartan
Why stopped
DSMC recommendation due to futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-16